Kepler Capital Markets set a CHF 86 price objective on Novartis (VTX:NOVN) in a research note published on Tuesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. set a CHF 89 target price on Novartis and gave the stock a sell rating in a research report on Wednesday, January 2nd. Deutsche Bank set a CHF 96 target price on Novartis and gave the stock a neutral rating in a research report on Friday, January 11th. Barclays set a CHF 75 target price on Novartis and gave the stock a sell rating in a research report on Wednesday, January 16th. UBS Group set a CHF 85 target price on Novartis and gave the stock a neutral rating in a research report on Friday, January 18th. Finally, Goldman Sachs Group set a CHF 110 target price on Novartis and gave the stock a buy rating in a research report on Thursday, January 24th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. Novartis presently has a consensus rating of Hold and a consensus price target of CHF 89.33.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: Why is Cost of Capital Important?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.